A Closer Look at Opioid-Induced Adrenal Insufficiency : A Narrative Review
Among several opioid-associated endocrinopathies, opioid-associated adrenal insufficiency (OIAI) is both common and not well understood by most clinicians, particularly those outside of endocrine specialization. OIAI is secondary to long-term opioid use and differs from primary adrenal insufficiency. Beyond chronic opioid use, risk factors for OIAI are not well known. OIAI can be diagnosed by a variety of tests, such as the morning cortisol test, but cutoff values are not well established and it is estimated that only about 10% of patients with OIAI will ever be properly diagnosed. This may be dangerous, as OIAI can lead to a potentially life-threatening adrenal crisis. OIAI can be treated and for patients who must continue opioid therapy, it can be clinically managed. OIAI resolves with opioid cessation. Better guidance for diagnosis and treatment is urgently needed, particularly in light of the fact that 5% of the United States population has a prescription for chronic opioid therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
International journal of molecular sciences - 24(2023), 5 vom: 26. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Coluzzi, Flaminia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adrenal crisis |
|---|
| Anmerkungen: |
Date Completed 14.03.2023 Date Revised 14.03.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/ijms24054575 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354076426 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354076426 | ||
| 003 | DE-627 | ||
| 005 | 20231226061437.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijms24054575 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1180.xml |
| 035 | |a (DE-627)NLM354076426 | ||
| 035 | |a (NLM)36902007 | ||
| 035 | |a (PII)4575 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Coluzzi, Flaminia |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Closer Look at Opioid-Induced Adrenal Insufficiency |b A Narrative Review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.03.2023 | ||
| 500 | |a Date Revised 14.03.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Among several opioid-associated endocrinopathies, opioid-associated adrenal insufficiency (OIAI) is both common and not well understood by most clinicians, particularly those outside of endocrine specialization. OIAI is secondary to long-term opioid use and differs from primary adrenal insufficiency. Beyond chronic opioid use, risk factors for OIAI are not well known. OIAI can be diagnosed by a variety of tests, such as the morning cortisol test, but cutoff values are not well established and it is estimated that only about 10% of patients with OIAI will ever be properly diagnosed. This may be dangerous, as OIAI can lead to a potentially life-threatening adrenal crisis. OIAI can be treated and for patients who must continue opioid therapy, it can be clinically managed. OIAI resolves with opioid cessation. Better guidance for diagnosis and treatment is urgently needed, particularly in light of the fact that 5% of the United States population has a prescription for chronic opioid therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a adrenal crisis | |
| 650 | 4 | |a adrenal insufficiency | |
| 650 | 4 | |a chronic pain | |
| 650 | 4 | |a endocrine | |
| 650 | 4 | |a hypothalamic-pituitary-adrenal axis | |
| 650 | 4 | |a opioid use disorder | |
| 650 | 4 | |a opioids | |
| 650 | 4 | |a pituitary | |
| 650 | 7 | |a Analgesics, Opioid |2 NLM | |
| 650 | 7 | |a Hydrocortisone |2 NLM | |
| 650 | 7 | |a WI4X0X7BPJ |2 NLM | |
| 700 | 1 | |a LeQuang, Jo Ann K |e verfasserin |4 aut | |
| 700 | 1 | |a Sciacchitano, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Scerpa, Maria Sole |e verfasserin |4 aut | |
| 700 | 1 | |a Rocco, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Pergolizzi, Joseph |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of molecular sciences |d 2008 |g 24(2023), 5 vom: 26. Feb. |w (DE-627)NLM185552161 |x 1422-0067 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:5 |g day:26 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/ijms24054575 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 5 |b 26 |c 02 | ||